Future Predictions for Intravenous and Subcutaneous Biologics

The new biosimilar, Tyenne, was approved in both an IV and a subcutaneous forms to treat inflammatory conditions such as arthritis.

Celltrion’s application is based on data from a phase 3 trial of patients with rheumatoid arthritis comparing its biosimilar with Actemra.

The IV formulation, a monthly 30-minute, weight-based dosing option, has a wholesale acquisition cost of $2,115 per vial. It will be available in the fourth quarter.

Biogen is still evaluating launch timeline for Tofidence, and information on pricing will be available closer to launch.

Feelings of depression and stress are partly to blame for lower fitness levels among people with rheumatoid arthritis.

The results argue for close clinical management of people with rheumatoid arthritis, say the authors of the meta-analysis that included 14 studies.